We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Cara Therapeutics Inc
20 own
52 watching
Current Price
$0
$0.1
(3.07%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
166.23M
52-Week High
12.98
52-Week Low
2.94
Average Volume
0.72M
Dividend Yield
--
P/E Ratio
107.2671
Market Capitalization166.23M52-Week High12.9852-Week Low2.94Average Volume0.72MDividend Yield--P/E Ratio107.2671What does the Cara Therapeutics Inc do?
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. It is developing product candidates that target the body's peripheral nervous system. The company's lead product candidate comprises I.V. CR845, which is in Phase III clinical trials for the treatment of patients with acute postoperative pain in adult patients, as well as in Phase II/III clinical trial for the treatment of uremic pruritus disease. It is also developing Oral CR845 that is in Phase IIb clinical trial to treat moderate-to-severe acute and chronic pain, as well as in Phase I clinical trial to treat uremic pruritus; and CR701, which is in preclinical trial for the treatment of neuropathic and inflammatory pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845 for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845 in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
Read More
How much money does Cara Therapeutics Inc make?
News & Events about Cara Therapeutics Inc.
Globe Newswire
1month ago
STAMFORD, Conn., April 10, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc.(Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive ...
Benzinga
2 months ago
read more...
Ticker Report
8 months ago
Cara Therapeutics, Inc. (NASDAQ:CARA Get Rating) Director Martin Vogelbaum sold 10,800 shares of Cara Therapeutics stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $10.28, for a total value of $111,024.00. Following the transaction...
Globe Newswire
9 months ago
Kapruvia (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients Therapy recently approved in Canada under the brand name KORSUVA Regulatory decisions in Australia and Singapore ...
Globe Newswire
1 year ago
First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patientsFirst launches in Europe expected in H2 2022 ST. GALLEN, Switzerland and STAMFORD, Conn., April 28, 2022 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (...
Frequently Asked Questions
Frequently Asked Questions
What is Cara Therapeutics Inc share price today?
Can Indians buy Cara Therapeutics Inc shares?
How can I buy Cara Therapeutics Inc shares from India?
Can Fractional shares of Cara Therapeutics Inc be purchased?
What are the documents required to start investing in Cara Therapeutics Inc stocks?
What is today’s traded volume of Cara Therapeutics Inc?
What is today’s market capitalisation of Cara Therapeutics Inc?
What is the 52-Week High and Low Range of Cara Therapeutics Inc?
What percentage is Cara Therapeutics Inc down from its 52-Week High?
What percentage is Cara Therapeutics Inc up from its 52-Week Low?
Current Price
$0
$0.1
(3.07%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.